anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

205,021-205,080 of 319,975

filter-aware
36
The slide includes a visual comparison of tumor burden in mice models (Vehicle vs ONC201 vs ONC212).Chimerix | Investor Presentation Deck | 41 slides · Chimerix
Pitch deck Investor relations 1 hit
37
Includes a dot plot showing significant reduction in viral lung titer across various treatment initiation times compared to vehicle.Chimerix | Investor Presentation Deck | 41 slides · Chimerix
Pitch deck Investor relations 1 hit
38
Chimerix | Investor Presentation Deck | 41 slidesChimerix | Investor Presentation Deck | 41 slides · Chimerix
Pitch deck Investor relations 1 hit
39
Chimerix | Investor Presentation Deck | 41 slidesChimerix | Investor Presentation Deck | 41 slides · Chimerix
Pitch deck Investor relations 1 hit
40
The slide uses a process-like flow to connect financial strength to clinical milestones.Chimerix | Investor Presentation Deck | 41 slides · Chimerix
Pitch deck Investor relations Loop · Why Now1 hit
41
Chimerix | Investor Presentation Deck | 41 slidesChimerix | Investor Presentation Deck | 41 slides · Chimerix
Pitch deck Investor relations 1 hit
01
Slide 1
Cipher Mining | Investor Presentation Deck | 18 slidesCipher Mining | Investor Presentation Deck | 18 slides · Cipher Mining
Pitch deck Investor relations 1 hit
02
Cipher Mining | Investor Presentation Deck | 18 slidesCipher Mining | Investor Presentation Deck | 18 slides · Cipher Mining
Pitch deck Investor relations 1 hit
03
The slide highlights operational efficiency and growth progress.Cipher Mining | Investor Presentation Deck | 18 slides · Cipher Mining
Pitch deck Investor relations Beat · Traction1 hit
04
Cipher Mining | Investor Presentation Deck | 18 slidesCipher Mining | Investor Presentation Deck | 18 slides · Cipher Mining
Pitch deck Investor relations Beat · Traction1 hit
05
The slide uses a process flow diagram to explain the mining economics.Cipher Mining | Investor Presentation Deck | 18 slides · Cipher Mining
Pitch deck Investor relations Beat · Business Model1 hit
06
The slide uses a timeline-annotated line chart to correlate market events with price movements.Cipher Mining | Investor Presentation Deck | 18 slides · Cipher Mining
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
07
The slide combines operational status updates with a growth trajectory chart.Cipher Mining | Investor Presentation Deck | 18 slides · Cipher Mining
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
08
The slide presents four primary KPIs for a specific mining site, supported by aerial photography.Cipher Mining | Investor Presentation Deck | 18 slides · Cipher Mining
Pitch deck Investor relations Beat · Traction1 hit
09
Includes site photos and detailed footnotes regarding joint venture ownership and cost calculations.Cipher Mining | Investor Presentation Deck | 18 slides · Cipher Mining
Pitch deck Investor relations Beat · Traction1 hit
10
Includes facility photo and a timeline of hashrate deployment.Cipher Mining | Investor Presentation Deck | 18 slides · Cipher Mining
Pitch deck Investor relations Beat · Traction1 hit
11
The chart illustrates a specific 24-hour period where energy prices spiked, showing the difference between mining revenue and energy costs.Cipher Mining | Investor Presentation Deck | 18 slides · Cipher Mining
Pitch deck Investor relations 1 hit
12
Cipher Mining | Investor Presentation Deck | 18 slidesCipher Mining | Investor Presentation Deck | 18 slides · Cipher Mining
Pitch deck Investor relations Beat · Financials1 hit
13
Financial statement disclosure slide.Cipher Mining | Investor Presentation Deck | 18 slides · Cipher Mining
Pitch deck Investor relations Beat · Financials1 hit
14
Note: In thousands, except for share and per share amountsCipher Mining | Investor Presentation Deck | 18 slides · Cipher Mining
Pitch deck Investor relations Beat · Financials1 hit
15
Contains two distinct reconciliation tables: one for operating income/loss and one for net income/loss and EPS.Cipher Mining | Investor Presentation Deck | 18 slides · Cipher Mining
Pitch deck Investor relations Beat · Financials1 hit
16
Cipher Mining | Investor Presentation Deck | 18 slidesCipher Mining | Investor Presentation Deck | 18 slides · Cipher Mining
Pitch deck Investor relations Beat · Financials1 hit
17
Standard financial disclosure table.Cipher Mining | Investor Presentation Deck | 18 slides · Cipher Mining
Pitch deck Investor relations Beat · Financials1 hit
18
Note: In thousandsCipher Mining | Investor Presentation Deck | 18 slides · Cipher Mining
Pitch deck Investor relations Beat · Financials1 hit
01
Slide 1
Features a molecular visualization with a target reticle.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations 1 hit
02
Compass Therapeutics | Investor Presentation Deck | 40 slidesCompass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations 1 hit
03
The slide uses a ribbon-style list format to categorize key company pillars.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations 1 hit
04
The chart uses a Gantt-style visualization to represent clinical trial progress across different indications.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations 1 hit
05
The slide uses a two-tier organizational structure (Senior Executive Team vs Vice Presidents) and includes a footer for the Chairman of the Board.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations 1 hit
06
The slide features a large compass-like icon, suggesting a focus on direction or a specific target.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations 1 hit
07
The slide illustrates the mechanism of action of CTX-009 as a bispecific antibody and compares the effects of single-agent anti-VEGF vs anti-DLL4 blockade.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations 1 hit
08
Compass Therapeutics | Investor Presentation Deck | 40 slidesCompass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations 1 hit
09
Clinical trial data summary for CTX-009.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Hypothesis Test1 hit
10
The chart displays individual patient responses categorized by cancer type (Gastric, CRC, Other) and dosage (mpk).Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Hypothesis Test1 hit
11
The table highlights Partial Response rates with a red border.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Hypothesis Test1 hit
12
The chart uses a standard waterfall plot to visualize clinical efficacy (tumor shrinkage).Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Hypothesis Test1 hit
13
Includes footnotes regarding clinical trial context for hypertension and cytopenia.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Hypothesis Test1 hit
14
Compass Therapeutics | Investor Presentation Deck | 40 slidesCompass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Hypothesis Test1 hit
15
The slide illustrates a standard Simon 2-stage design, a common statistical framework for phase II oncology trials.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations 1 hit
16
The table highlights patient age, gender, ECOG status, prior therapies, and BTC subtypes.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations 1 hit
17
The chart is a classic waterfall plot used in oncology to demonstrate drug efficacy.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations 1 hit
18
Standard clinical trial swimmer plot visualization.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations 1 hit
19
The slide presents key clinical efficacy endpoints for a Phase 2 study.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations 1 hit
20
Standard clinical trial survival analysis plots (Kaplan-Meier).Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations 1 hit
21
The slide compares clinical trial data for a specific drug combination against known safety profiles of standard-of-care components.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations 1 hit
22
The table compares a mixed 2L/3L cohort (CTX-009) against historical 1L and 2L benchmarks.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Confession1 hit
23
The slide compares internal trial data for CTX-009 against historical benchmarks (FOLFOX and TOPAZ-1) to demonstrate efficacy.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Confession1 hit
24
The slide outlines a randomized clinical trial structure with two arms (CTX-009 + Paclitaxel vs Paclitaxel alone) and a crossover provision.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations 1 hit
25
The slide uses a table for market sizing and a structured layout to contrast 1L and 2L treatment options.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
26
The slide outlines a standard Simon 2-stage design where recruitment stops if the objective response rate (ORR) threshold is not met in the first stage.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
27
The slide uses a table for epidemiological data and a horizontal layout to represent the treatment pathway.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
28
The slide uses a simple sequential block layout to represent a development roadmap.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations 1 hit
29
Compass Therapeutics | Investor Presentation Deck | 40 slidesCompass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations 1 hit
30
The slide highlights clinical efficacy in Phase 1a and 1b trials for various cancers.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations 1 hit
31
The slide uses a before-and-after visual comparison of CT scans to demonstrate drug efficacy.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations 1 hit
32
Compass Therapeutics | Investor Presentation Deck | 40 slidesCompass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations 1 hit
33
Compass Therapeutics | Investor Presentation Deck | 40 slidesCompass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations 1 hit
34
Shows a process flow from initial synergistic discovery to the final optimized bispecific molecule (CTX-8371) and its validation data.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations 1 hit
35
The slide uses a visual comparison framework to contrast standard PD-1 blockers with the proprietary CTX-8371 mechanism.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations 1 hit
36
The slide shows tumor volume over time, tumor growth inhibition percentages, individual tumor growth trajectories, and a summary table of cure rates.Compass Therapeutics | Investor Presentation Deck | 40 slides · Compass Therapeutics
Pitch deck Investor relations 1 hit